Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis

Condition:   Multiple Sclerosis Intervention:   Drug: Gilenya®; Novartis Pharmaceuticals Corporation Sponsor:   Universitätsklinikum Hamburg-Eppendorf Recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials